<DOC>
	<DOCNO>NCT00886509</DOCNO>
	<brief_summary>The purpose study patient stable coronary artery disease ( CAD ) treatable PCI ( percutaneous coronary intervention ) evaluate long-term efficacy safety subcutaneously apply , pegylated granulocyte colony stimulate factor ( Pegfilgrastim , PEG-G-CSF ; NeulastaÂ® , Amgen Switzerland ) regard promotion collateral growth .</brief_summary>
	<brief_title>Peg-Granulocyte-Colony Stimulating Factor ( GCSF ) Coronary Collateral Growth Coronary Artery Disease Patients</brief_title>
	<detailed_description>Coronary artery disease ( CAD ) lead cause death industrialized country . Current revascularization therapy PCI surgical revascularization . However , inherent procedure-related risk fact , progression CAD prevent . Additionally , one fourth CAD patient amenable standard revascularization therapy . Thus , need alternative therapy . The coronary collateral circulation prevalent human , CAD amount collateral flow pivotal protective factor respect infarct size , all-cause- cardiac mortality . Coronary collateral growth promotion alternative conventional revascularization achieve cytokine-based approach ( e.g . colony-stimulating factor-therapy ) human . The goal collateral promotion reduce myocardial damage case coronary occlusion .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . 1 3vessel coronary artery disease ( CAD ) 3 . Stable angina pectoris 4 . At least 1 stenotic lesion suitable PCI 5 . No Qwave myocardial infarction area undergo CFI measurement 6 . Written inform consent participate study 1 . Acute myocardial infarction 2 . Unstable CAD 3 . CAD treat best CABG 4 . Patients overt neoplastic disease 5 . Patients diabetic retinopathy 6 . Liver kidney disease 7 . Premenopausal woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Stable</keyword>
	<keyword>Coronary Collaterals</keyword>
	<keyword>Therapeutic Collateral Promotion ( TCP )</keyword>
</DOC>